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Abstract
Tau is an axonal microtubule-binding protein. Tau pathology in brain and increased tau concentration in the cerebrospinal 
fluid (CSF) are hallmarks of Alzheimer’s disease (AD). Most of tau in CSF is present as fragments. We immunoprecipitated 
tau from CSF and identified several endogenous peptides ending at amino acid (aa) 123 or 224 using high-resolution mass 
spectrometry. We raised neo-epitope-specific antibodies against tau fragments specifically ending at aa 123 and 224, respec-
tively. With these antibodies, we performed immunohistochemistry on brain tissue and designed immunoassays measuring 
N-123, N-224, and x-224 tau. Immunoassays were applied to soluble brain fractions from pathologically confirmed subjects 
(81 AD patients, 33 controls), CSF from three cross-sectional and two longitudinal cohorts (a total of 133 AD, 38 MCI, 20 
MCI-AD, 31 PSP, 15 CBS patients, and 91 controls), and neuronally- and peripherally-derived extracellular vesicles (NDEVs 
and PDEVs, respectively) in serum from four AD patients and four controls. Anti-tau 224 antibody stained neurofibrillary 
tangles and neuropil threads, while anti-tau 123 only showed weak cytoplasmic staining in AD. N-224 tau was lower in the 
AD soluble brain fraction compared to controls, while N-123 tau showed similar levels. N-224 tau was higher in AD com-
pared to controls in all CSF cohorts (p < 0.001), but not N-123 tau. Decrease in cognitive performance and conversion from 
MCI to AD were associated with increased baseline CSF levels of N-224 tau (p < 0.0001). N-224 tau concentrations in PSP 
and CBS were significantly lower than in AD (p < 0.0001) and did not correlate to t-tau and p-tau. In a longitudinal cohort, 
CSF N-224 tau levels were stable over 6 months, with no significant effect of treatment with AChE inhibitors. N-224 tau 
was present in NDEVs, while N-123 tau showed comparable concentrations in both vesicle types. We suggest that N-123 tau 
is produced both in CNS and PNS and represents a general marker of tau metabolism, while N-224 tau is neuron-specific, 
present in the tangles, secreted in CSF, and upregulated in AD, suggesting a link between tau cleavage and propagation, 
tangle pathology, and cognitive decline.
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Introduction
Alzheimer’s disease (AD) is the most common neurodegen-
erative tauopathy and is responsible for 75% of the 35.6 mil-
lion dementia cases worldwide [44]. As the world population 
ages, the frequency is expected to double by 2030 and tri-
ple by 2050 [44]. At present, the only therapeutic option 
is symptomatic, while disease-modifying therapies are still 
under development [37].
The classical pathological hallmarks of AD consist of 
deposition of amyloid beta (Aβ) in cortical plaques and 
hyperphosphorylation of tau and formation of neurofibril-
lary tangles (NFT) causing neuronal degeneration [37]. In 
cerebrospinal fluid (CSF), these pathological changes are 
reflected by low Aβ42 levels, low Aβ42/Aβ40 ratio, and 
high levels of phosphorylated tau (p-tau) and total tau (t-tau) 
[12, 32]. Tau pathology, namely the aggregation of tau and 
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formation of tangles, is described as a mechanism common 
to AD and primary tauopathies, such as corticobasal neu-
rodegeneration (CBD) and progressive supranuclear palsy 
(PSP). Tau pathology is predominantly localized to neurons 
in AD, while in primary tauopathies is also present in the 
glia in filamentous (tufted astrocytes, in PSP) or more dif-
fuse form (astrocytic plaques, in CBD). Their clinical pres-
entation is very different, with AD being primarily charac-
terized by memory impairment and PSP by parkinsonism; 
CBD has a very heterogeneous clinical presentation, rang-
ing from parkinsonism to AD-like symptoms, which goes 
under the name of corticobasal syndrome (CBS) [7]. The use 
of AD biomarkers to better differentiate AD-like CBS has 
been proposed to help diversify the therapeutic options [15]. 
Nonetheless, several studies on CSF in primary tauopathies 
show normal or even low concentrations of t-tau and p-tau, 
in stark contrast to the increased levels seen in AD, and no 
CSF profile specific for primary tauopathies has been estab-
lished [15, 21, 41, 42].
From a methodological perspective, most of the data on 
CSF t-tau come from studies based on commercially availa-
ble immunoassays that rely on a combination of monoclonal 
antibodies (AT120, HT7, and BT2) having epitopes in the 
mid-region of the protein (Fig. 1a), but several studies sug-
gest that tau is present as different fragments in both brain 
extract and CSF [3, 9, 10, 22, 30, 35, 38]. A recent study 
used high-performance liquid chromatography (HPLC) sep-
aration of CSF proteins, followed by Western blotting with 
tau antibodies binding to different tau domains, to show that 
CSF tau is composed of a series of fragments, with N-ter-
minal and mid-region tau representing the most abundant 
variants in CSF [30]. Mass spectrometry (MS) has also 
proven helpful to characterize tau species in detail. How-
ever, CSF is a complex matrix and several pre-treatments 
had to be tested to reach the adequate sensitivity to detect 
tau and its variants in CSF [9, 10, 35]. Different groups 
have detected tau peptides spanning from the N- to the 
C-terminus of the protein in CSF [9, 10, 35]. However, the 
most reproducible result so far is increased concentrations 
of C-terminally truncated tau forms in AD, which fits well 
with the highly reproducible results that have been gener-
ated using regular t-tau and p-tau immunoassays [32], whilst 
the other neurodegenerative dementias, including primary 
tauopathies, are surprisingly normal [9, 10].
A possible explanation for the AD specificity of CSF 
tau profiles has been proposed, based on an in vivo model 
using stable-isotope labeling on human central nervous 
system (CNS) and iPSC-derived neurons [36]. The results 
show that most tau in CSF and cell media lack the microtu-
bule-binding region and more C-terminal parts, that these 
tau forms are actively secreted from neurons, and that the 
secretion appears to be stimulated by Aβ exposure [36]. CSF 
tau concentrations generated using the currently available 
assays would thus not be specific for tangle pathology or 
neurodegeneration but rather reflect a neuronal response to 
Aβ pathology.
To identify novel tau biomarkers that might better reflect 
AD-type neurodegeneration, we used N-terminal and mid-
region-specific antibodies for enrichment of tau species fol-
lowed by MS analysis using both bottom–up and top–down 
approaches. We identified a large number of endogenous 
and tryptic peptides belonging to two different pools of tau, 
Fig. 1  Overview of standard (a) 
and novel (b, c) immunoassays 
for t-tau and tau fragments: the 
traditional assay only detects 
the mid-region of tau; our novel 
immunoassays detect fragments 
ending at aa123 and aa224
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one starting at the N-terminal and ending at aa 123 through 
129 and another mid-region pool covering aa 144–224 (tau 
441 numbering). We then immunized mice to generate 
neo-epitope-specific antibodies against aa 123 and 224. We 
applied these unique antibodies for further studies evaluating 
the link between these specific tau fragments and tau pathol-
ogy. We immunohistochemically stained post-mortem brain 
and developed immunoassays to specifically quantify the 
respective fragment in soluble brain extracts and CSF from 
AD, PSP, CBS patients, and controls. We also evaluated 
the N-224 fragment stability as biomarker in a longitudinal 
cohort under treatment with acetylcholinesterase (AChE) 
inhibitors. Furthermore, we analyzed the two fragments in 
neuronally derived extracellular vesicles (NDEV), including 
exosomes, isolated from serum, to study the potential role 
of exosomes in tau propagation. The present study aimed 
to characterize new tau fragments and describe a possible 
model for their distribution, function, and role in the patho-
genesis of AD.
Materials and methods
Brain tissue extraction for immunoprecipitation
Brain tissue for the immunoprecipitation mass spectrom-
etry (IP-MS) analysis was from the Netherlands Brain Bank. 
Samples were collected from the superior parietal lobe of 
control brains (Braak 0–I) 4–7 h post-mortem and stored 
at − 80 °C. Brain material was kept on dry ice and 100 mg 
samples were excised and put in TBS solution (20 mM Tris, 
137 mM NaCl, and pH 7.6) containing protease inhibitor 
(Protease Inhibitor Cocktail tablets, Roche, Cat no: 11 697 
498 001, Lot nr: 14,251,300) and homogenized with a motor 
homogenizer to final a tissue:TBS ratio of 1:5. The tissue 
homogenates were further diluted 1:2 in TBS solution with 
protease inhibitor and vortexed. The samples were then cen-
trifuged for 60 min at 31,000×g, + 4 °C. Supernatants were 
collected, aliquoted, and stored at − 80 °C pending analysis. 
Aliquots were further diluted 1:40 in TBS prior to IP.
Immunoprecipitation
Aliquots (4 µg) of Tau 12 (binding region aa 9–18, Nordic 
Biosite), HT7 (aa 159–163, Thermo Scientific), and BT2 
(aa 194–198, Thermo Scientific) were added to 50 µL/each 
magnetic Dynabeads M-280 and incubated 2 h on a rock-
ing platform at room temperature. The beads were washed 
three times with double volume of PBS (10 mM Na-phos-
phate, 0.15 M NaCl, and pH 7.4). The antibody was cross-
linked using 20 mM dimethyl pimelimidate dihydrochloride 
(DMP; Sigma-Aldrich) and 0.2 M triethanolamine (pH 8.2, 
Sigma-Aldrich) according to the manufacturer’s product 
description. The cross-linked beads were washed twice in 
PBS and blocked with Roti-Block (Carl Roth) for 1 h on 
a rocking platform at room temperature. Antibody-conju-
gated beads and Tween 20 (final concentration in the sample: 
0.025%) were added to 3 mL CSF or 7 µL of a TBS-soluble 
fraction of brain homogenate diluted in 270 µL PBS. For 
some of the samples intended for tryptic digestion, 100 fmol 
of a 13C15N lysine- and arginine-labeled tau 1N4R protein 
standard (provided by Dr. Thomas McAvoy, Merck Research 
Laboratories) were added. Samples were incubated over-
night on a rocking platform at + 4 °C. The magnetic beads/
sample solution was transferred to a magnetic particle pro-
cessor (KingFisher, Thermo Fisher Scientific) (tube 1). The 
following three wash steps (tubes 2–4) were conducted for 
10 s in 1 mL of each washing buffer: 0.025% Tween 20 in 
PBS (tube 2), PBS (tube3), and 50 mM ammonium hydro-
gen carbonate (tube 4, pH 8.0). Tau was eluted from the 
beads by adding 100 µL 0.5% formic acid (tube 5) for 4 min. 
The eluted fractions were transferred to 0.65 mL prelubri-
cated microcentrifuge tubes (Costar, Cat. 3206) and dried 
in a vacuum centrifuge. After drying, 10 µL of a solution 
of 1 µg trypsin in 390 µL 50 mM ammonium hydrogen 
carbonate was added to half of the samples and incubated 
overnight at + 37 °C. The reaction was stopped by adding 
2 µL of 10% formic acid in ultra-pure water. The other half 
was analyzed intact for endogenous peptides. Samples were 
dried in a vacuum centrifuge and stored at − 80 °C pending 
analysis. Following the same protocol described above, we 
immunoprecipitated tau from CSF and brain lysate with the 
neo-epitope-specific antibodies to verify their specificity.
LC–MS/MS analysis
NanoLC coupled to ESI high-resolution hybrid quadrupole-
orbitrap MS was performed with a Dionex 3000 system and 
either a Q Exactive or an Orbitrap Fusion (all three from 
Thermo Fisher Scientific, Inc.) in a similar way as previously 
published [15]. Immunoprecipitated samples were recon-
stituted in 7 µL 8% formic acid/8% acetonitrile in water. 
Samples (6 µl) were loaded onto an Acclaim PepMap C18 
trap column (length 20 mm, internal diameter 75 µm, par-
ticle size 3 µm, pore size 100 Å, Thermo Fisher Scientific, 
Inc.) for desalting and sample clean-up. Sample loading 
buffer was 0.05% trifluoroacetic acid in water. Separation 
was performed by reversed-phase Acclaim PepMap C18 
analytical columns (lengths 150 or 500 mm, internal diam-
eter 75 µm, particle size 2 µm, pore size 100 Å, and Thermo 
Fisher Scientific, Inc.). Separation was performed at a flow 
rate of 300 or 150 nL/min by applying a 50-min-long linear 
gradient from 3 to 40% B. Buffer A was 0.1% formic acid 
in water and buffer B was 0.1% formic acid/84% acetoni-
trile in water. The mass spectrometer was set to operate in 
data-dependent mode using higher energy collision-induced 
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dissociation (HCD) for ion fragmentation. For endogenous 
peptides, the acquisition parameters were optimized for large 
fragments. Acquisition settings were the same for MS and 
MS/MS acquisitions for a better quality MS/MS data: resolu-
tion setting 70,000, 1 microscan, target values 106, and trap 
injection time 250 ms. For trypsinated samples, the MS/MS 
resolution setting was 17,500 and the trap injection time 
was 60 ms.
Processing of LC–MS/MS data
LC–MS/MS acquisitions of tryptic digests were processed 
directly using Proteome Discoverer v1.4 (Thermo Fisher 
Scientific, Inc.) and Mascot database search software v2.6.1 
(Matrix Science). Searches were made against both Uni-
prot and a custom made tau-only database. Acquisitions of 
non-digested samples were processed using Mascot Dae-
mon v2.6/Mascot Distiller v2.6.3 (both Matrix Science) for 
charge and isotope deconvolution before submitting searches 
using Mascot. The same databases as for the digested 
samples were utilized. Processing and search settings are 
described in [17] and supplementary information.
Expression of recombinant Tau 123 and 224
Tau 123 (aa 1–123 of Tau F) and Tau 224 (aa 1–224) were 
PCR amplified using primers containing 5′ Sgf I and 3′ Not 
I sites with cDNA for Tau F (RC213312, Origene) as tem-
plate. The PCR fragments were purified and cloned into 
Sgf I/Not I digested pEX_N_His_GST expression plasmid 
(PS100028, OriGene Technologies). 5′ primer sequence 
was TTC TAA GCG ATC GCC ATG GCT GAG CCCC, 3′ 
primer sequence for the 123 fragment was TAA AGC GGC 
CGC TTA GGT CAC GTG ACC AGC AGCTT, and 3′ primer 
sequence for the 224 fragment was TAA AGC GGC CGC TTA 
CTT GGG CTC CCG GGT GGGT. Constructs were sequenced 
and transfected into E. coli BL21 (DE3). E. coli BL21 (DE3) 
containing the different constructs was incubated overnight 
in 50 mL LB medium with ampicillin at a concentration 
of 100 µg/mL. The overnight culture was used to inoculate 
1 L of LB media with ampicillin (100 µg/mL), and when 
OD600 reached 0.4–0.6, protein expression was induced 
with 0.5 mM IPTG for 4 h at + 37 °C. The culture was cen-
trifuged at 5500×g for 20 min at + 4 °C and the dry weight 
was calculated. The pellet was stored at − 20 °C pending 
purification. The pellet was resuspended in 5 mL/mg of 
lysis buffer (20 mM Tris, 150 mM NaCl, and 1% NP40 pH 
7.5) plus complete protease inhibitor (Roche) and incubated 
with rotation for 30 min at room temperature, after which 
the lysate was centrifuged at 17,000×g for 20 min at + 4 °C 
and the supernatant was collected. Protein extract was added 
to 50% Glutathione-Sepharose 4b (GE Healthcare) equili-
brated with PBS and incubated for 30 min with rotation at 
room temperature. Sepharose was washed with PBS and the 
GST-Tau fusion protein was incubated with elution buffer 
(100 mM Tris–HCl and 120 mM NaCl pH 8.0, with 20 mM 
glutathione) for 10 min. The unbound fusion protein was 
eluted and the incubation step was repeated four times. 
Thrombin cleavage of the GST-fusion protein bound to the 
GST Sepharose was done in PBS with 50 U thrombin for two 
and a half hours at room temperature. The cleaved, untagged 
protein was eluted with PBS containing protease inhibitor.
Generation of monoclonal antibodies
Monoclonal antibodies against the recombinant protein 
fragments were generated by immunization of 8-week-
old Balb/c mice with KLH-conjugated peptides (Caslo) in 
complete Freund’s adjuvant (Sigma). Peptide sequence was 
(KLH)-CEEAGIGDTPSLEDEAAGHVT for the 123 and 
(KLH)-CGG GRT PSLPTPPTREPK for the 224. After 2–3 
dosages with the recombinant protein fragment (approxi-
mately 75 µg/mouse), the spleen was removed and B cells 
were fused with the myeloma cell line SP2/0 following the 
standard procedures. Approximately 10 days after fusion, 
cell media were screened for the antibodies using full-length 
recombinant tau and recombinant protein fragments. Clones 
that reacted with the recombinant protein fragments but not 
with full-length tau and negative control protein were fur-
ther grown, subcloned, and subsequently frozen in liquid 
nitrogen. The isotype was determined using a commercially 
available kit (Pierce Rapid Isotyping Kit-Mouse). Finally, 
antibodies were purified using a protein G column (GE 
healthcare).
Immunohistochemistry
Immunohistochemical analysis of the tau antibodies was 
carried out on brains that were donated to the Queen Square 
Brain Bank for Neurological Disorders, UCL Institute of 
Neurology, University College London. Seven-micron-thick 
formalin-fixed paraffin-embedded tissue sections were cut 
from the frontal cortex of pathologically diagnosed AD 
cases and neurologically normal controls. Tau immunohis-
tochemistry required pressure cooker pre-treatment in citrate 
buffer pH 6.0. Endogenous peroxidase activity was blocked 
with 0.3% H202 in methanol and non-specific binding with 
10% dried milk solution. Tissue sections were incubated 
with the primary anti-tau 123, anti-tau 224, and AT8 (bind-
ing to Ser202 and Thr205) antibodies for 1 h at room tem-
perature, followed by biotinylated anti-mouse IgG (1:200, 
30 min; DAKO) and ABC complex (30 min; DAKO). Col-
our was developed with di-aminobenzidine/H202 [26]. Sec-
tions were viewed and imaged on a Nikon Eclipse.
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ELISA assay for Tau N‑123
The immunoassay N-123, detecting fragments going from 
the N-terminal (antibody-binding region: aa 9–18) to aa 123, 
was developed on an ELISA platform (Fig. 1b). 96-well 
plates were coated and incubated overnight at + 4 °C with 
in house antibody anti-tau 123 at a concentration of 6 µg/
mL in carbonate buffer (pH 9.6). After blocking and wash-
ing, 90 µL of titrated calibrator (123 recombinant tau frag-
ment) and sample were co-incubated with 10 µL of bioti-
nylated detection antibody Tau 12 (Nordic Biosite), at a 
final concentration of 0.617 µg/mL. CSF samples were run 
neat, brain tissue extracts were run at 50-fold dilution. After 
overnight incubation at + 4 °C, the plate was washed and 
incubated for 30 min with a streptavidin-HRP-conjugated 
solution (KemEnTek Diagnostics). After a final wash and 
addition of the chromogen tetramethylbenzidine (TMB 
ONE, KemEnTek Diagnostics), the plate was read on a 
Magellan reader at a wavelength of 450 nm.
Simoa assay for tau N‑224
The immunoassay (N-224) detecting fragments going from 
the N-terminal (antibody-binding region: aa 9–18) to aa 224 
was developed using single-molecule array (Simoa, Quan-
terix, Lexington, MA, USA) technology (Fig. 1c). Magnetic 
beads (Quanterix, Lexington, MA, USA) were conjugated 
with the capture antibody anti-tau 224 at 0.3 mg/mL accord-
ing to bead supplier’s conjugation protocol. Prior to each 
run, Tau 224 recombinant protein calibrator was serially 
diluted and the biotin-labeled detection antibody Tau 12 
(Nordic Biosite) was diluted to 0.5 µg/mL in PBS-Tween 
with 1% BSA. For each determination, 140,000 assay beads 
were washed and resuspended in 100  μL of CSF/brain 
extract, quality control sample, or calibrator. After a wash-
ing step, 20 µL of detection antibody was added followed 
by 30-min incubation. After a final wash, beads were resus-
pended in 100 µL streptavidin-conjugated β-galactosidase 
(SBG, Quanterix, Lexington, MA, USA) at 150 pM diluted 
in SBG Diluent (Quanterix, Lexington, MA, USA). Follow-
ing 5 min of incubation, the beads were washed and trans-
ferred together with resorufin-d-galactopyranoside substrate 
(RGP, Quanterix, Lexington, MA, USA) to an array of wells, 
each well only big enough to contain one bead. The array 
was imaged with a charge-coupled device (CCD) camera 
imaging system and the images were used to differentiate 
between empty beads and beads with bound analyte, giving 
a signal expressed as average enzyme per bead (AEB). To 
extract concentrations from AEBs, each sample AEB was fit-
ted to a four-parameter logistic curve plotted from the known 
concentrations of the Tau 224 calibrator run in parallel with 
the samples. Calibrator points were run in triplicates, while 
samples were run in duplicates. CSF samples were run neat 
and brain tissue extracts were run at 100,000-fold dilution.
ELISA assay for Tau x‑224
A second immunoassay (x-224) detecting N-terminally trun-
cated fragments ending at aa 224 (antibody-binding region: 
aa 159–198) was developed on an ELISA platform (Fig. 1c). 
96-well plates were coated and incubated overnight at + 4 °C 
within house antibody anti-tau 224 at a concentration of 
2 µg/mL. After blocking and washing, 75 µL of titrated cali-
brator (224 recombinant tau fragment) and neat CSF sample 
were co-incubated with 12.5 µL of mixed biotinylated detec-
tion antibody HT7 and BT2 (Thermo Scientific), at a final 
concentration of 0.0625 µg/mL. After overnight incubation 
at + 4 °C, the plate was washed and incubated for 30 min 
with a streptavidin-HRP-conjugated solution (KemEnTek 
Diagnostics). After a final wash and addition of the chro-
mogen tetramethylbenzidine (TMB ONE, KemEnTek Diag-
nostics), the plate was read on a Magellan reader at a wave-
length of 450 nm.
Brain tissue samples
All brain lysates were made from cryosectioned fusiform 
gyrus from 81 AD and 33 controls at Banner Sun Health 
Institute and classified by Braak stages [16]. This region 
was chosen due to its close proximity to the entorhinal cor-
tex and higher densities of NFTs than any other neocorti-
cal region. Subjects were consented, enrolled and annually 
assessed in the Arizona Study of Aging and Neurodegenera-
tive Disorders, and then autopsied in the Brain and Body 
Donation Program [11]. The protocol and consent are annu-
ally reviewed by an Institutional Review Board. Brain tis-
sue was collected 5 h or less after death and stored until 
used at − 80 °C. The cryosections were lysed in RIPA buffer 
with protease inhibitors (Protease Inhibitor Cocktail tablets, 
Roche) using the Qiagen TissueLyzer to a final concentra-
tion of 2–3 mg/ml, as measured with BCA Protein Assay kit 
(Pierce). Samples were further diluted to 1:50 for the N-123 
and t-tau measurements and to 1:100,000 for the N-224 
measurement in their respective assay buffer-containing pro-
tease inhibitor (Protease Inhibitor Cocktail tablets, Roche).
CSF collection and biomarker analyses
All CSF samples were collected by lumbar puncture in the 
L3/L4 or the L4/L5 inter-space, in the morning. The first 
12 mL of CSF were collected in a polypropylene tube and 
immediately transported to the local laboratory and centri-
fuged (10 min at 1800g at + 20 °C). The supernatant was 
gently mixed to avoid possible gradient effects, aliquoted 
in polypropylene tubes, and stored at − 80 °C. CSF t-tau 
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and p-tau concentrations were measured using ELISA 
 (INNOTEST® htau Ag and PHOSPHO_TAU (181P), 
Fujirebio) as previously described [13, 43]. CSF Aβ1-42 
was measured using an ELISA  (INNOTEST® Aβ1-42), spe-
cifically constructed to measure Aβ starting at amino acid 1 
and ending at amino acid 42 [6].
Discovery CSF cohort
Non-AD subjects (n = 20) were patients referred to the 
hospital for the evaluation of psychiatric or neurological 
symptoms, but with basic (cell count, albumin ratio, and 
IgG index) and core (Aβ1-42, t-tau, and p-tau) CSF bio-
markers within normal ranges. Patients with AD (n = 20) 
had a clinical diagnosis of AD along with biomarker posi-
tive CSF (Supplementary Table 4a). Samples were selected 
based on biomarker cut-offs for Aβ1-42, t-tau, and p-tau181. 
Cut-offs used to for a biomarker positive profile was Aβ1-
42 < 550 ng/L, t-tau > 400 ng/L, and p-tau > 80 ng/L. The 
CSF sample aliquots used were de-identified left-over ali-
quots from clinical routine analyses, following a procedure 
approved by the Ethics Committee at University of Gothen-
burg (EPN 140,811).
Validation CSF cohort
The CSF sample aliquots used were from the Memory Clinic 
at the University of Lund (Dnr 695/2008). Included par-
ticipants were characterized as AD (n = 46), according to 
the criteria of National Institute of Neurological and Com-
municative Disorders and Stroke and the AD and Related 
Disorders Association [19, 28], and healthy volunteers as 
the control group (n = 50) (Supplementary Table 4b). The 
applied IWG-2 criterion for allocation to the AD group was 
a low concentration of Aβ1-42 (< 550 ng/L) with a high 
level of t-tau (> 400 ng/L) or p-tau181 (> 80 ng/L).
Longitudinal CSF cohort
Baseline CSF samples from 16 AD, 38 MCI, 20 MCI-AD, 
and 21 other neurological diseases (OND) subjects were col-
lected at the Center for Memory Disturbances of the Uni-
versity of Perugia (Supplementary Table 5). All patients 
underwent a baseline clinical examination with a complete 
neuropsychological assessment and blood chemistry, brain 
CT, and/or MRI scan to exclude the other causes of cogni-
tive deficit. Subjects were clinically diagnosed according to 
the NIA-AA AD criteria [28] and Petersen’s MCI criteria 
[33], with AD CSF biomarkers (Aβ1-42, t-tau, and p-tau) 
used as support. Cognitive assessment at follow-up was per-
formed through MMSE every 6 months for ~ 2.3 years. OND 
subjects had no clinical or neuropsychological evidence of 
cognitive impairment and were diagnosed with Parkinson’s 
disease (n = 15), psychiatric disorder (n = 1), white-matter 
lesions (n = 2), Miller–Fisher syndrome (n = 1), epilepsy 
(n = 1), and paraneoplastic syndrome (n = 1). The study 
was conducted according to the Helsinki Declaration and 
approved by the local ethics committee (Prot. N. 19369/08/
AV).
PSP and CBS CSF cohort
Patients with parkinsonism were diagnosed at the Depart-
ment of Neurology, Movement Disorders Unit, Sahlgrenska 
University Hospital, Gothenburg, Sweden, by movement 
disorders specialists. Thirty-one subjects were diagnosed 
with probable or definite PSP according to the criteria from 
the National Institute of Neurological Disorders and Stroke 
and Society for Progressive Supranuclear Palsy (NINDS-
SPSP) [27]. Fifteen subjects were diagnosed with probable 
CBS according to the criteria from Armstrong et al. [7]. All 
patients underwent lumbar puncture as part of the diagnostic 
work-up. CSF biomarkers Aβ1-42, t-tau, and p-tau were ana-
lyzed at the Clinical Neurochemistry Laboratory, Sahlgren-
ska University Hospital, Mölndal, Sweden (Supplementary 
Table 6). Based on the concentrations of Aβ1-42, subjects 
were further divided in Aβ positive (Aβ+) and Aβ negative 
(Aβ−). The cut-off applied for an Aβ+ profile was the same 
as the discovery and validation cohorts (Aβ < 550 ng/L). Aβ- 
subjects were 15 in the PSP and seven in the CBS group. 
Concentrations of N-123 and N-224 were compared to the 
ones in the AD and control groups of the validation cohort; 
the ratio between QC samples from the different runs was 
used for normalization. The study was conducted according 
to the Helsinki Declaration and the collection of samples 
was approved by the Regional Ethical Board at the Univer-
sity of Gothenburg (n. 460–13, 462–95, and 210–95).
Biomarker stability study CSF cohort
CSF samples were collected during a 6-month multicenter 
open study on 51 patients with AD on continuous treatment 
with acetylcholine esterase (AChE) inhibitors, as previously 
described (Supplementary Table 7) [14, 23]. Briefly, all 
patients underwent a thorough clinical investigation which 
included medical history, physical, neurological, and psychi-
atric examinations. AD was diagnosed following NINCDS-
ADRDA criteria [29]. Exclusion criteria were: prominent 
frontal lobe symptoms, clinical or brain imaging signs of 
cerebrovascular disease, family history of dementia, treat-
ment with lithium, warfarin, memantine, antidepressants, 
and neuroleptics. MMSE was performed at baseline to select 
only mild  to moderate severity (MMSE score > 15) AD 
cases. Treatment with AChE inhibitors at stable doses had 
to be ongoing for at least 3 months prior to the study. Within 
4 weeks after enrolment, subjects underwent cognitive tests 
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MMSE and Alzheimer’s disease Assessment Scale, Cogni-
tive subscale (ADAS-Cog), and CSF tapping. Six months 
later, cognitive tests were repeated and a second CSF sample 
was taken. All patients gave informed consent to participate 
in the study. The study was conducted according to the Hel-
sinki Declaration and approved by the ethics committee at 
the University of Lund and Uppsala and at the Karolinska 
Institute, Stockholm, Sweden.
Isolation of NDEV and PDEV
EVs were isolated from human serum following a protocol 
previously described, with some alterations [31]. Briefly, 
0.5 mL of serum from four AD CSF biomarker positive 
and four AD CSF biomarker negative subjects were col-
lected and frozen. Cut-offs used to for a biomarker positive 
CSF profile were Aβ1-42 < 550 ng/L, t-tau > 400 ng/L, and 
p-tau > 80 ng/L. After thawing, 500 μl of Dulbecco’s solu-
tion were added to the samples. Samples were mixed, left for 
5 min at RT, and then centrifuged at 4000×g for 20 min at 
4 °C. Supernatants were transferred to new tubes and mixed 
with 252 μl  Exoquick® exosome precipitating solution (Sys-
tem Biosciences). Samples were incubated for 60 min at 4 °C 
and then centrifuged at 1500g for 20 min at 4 °C. Superna-
tants were discarded after centrifugation and the pellet was 
re-suspended in 0.5 ml  dH2O. Samples were incubated for 
1 h at 4 °C with 4 μg in 50 μL of 3% BSA of mouse anti-
human CD171 biotinylated antibody (eBio5G3) directed to 
neuronal L1 cell adhesion molecule (L1CAM). Next, 15 μL 
of streptavidin-agarose Ultralink resin (Thermo Scientific) 
was added with 25 μL of 3% BSA and incubated for 30 min 
at 4 °C with continuous mixing. Samples were centrifuged at 
200g for 10 min at 4 °C and the supernatants were saved for 
the analysis of PDEV, while the pellet was re-suspended in 
200 μL of 0.1 M glycine HCl by mixing for 10 s and centri-
fuged at 4500g for 10 min at 4 °C to detach L1CAM + EVs 
from the beads. Supernatants were transferred to new tubes 
and 25 μL 3% BSA and 15 μL of 1 M Tris–HCl was added. 
Exosomes were lysed by addition of 260 μL mammalian 
protein extraction reagent (M-PER; Thermo Scientific) and 
went through two freeze thaw cycles. Samples were stored 
at − 80 °C pending immunoassay analysis.
Statistical analysis
GraphPad Prism v7.02 (GraphPad Software, Inc., La Jolla, 
CA, USA) was used for the statistical analysis of discov-
ery, validation, longitudinal, and PSP/CBS cohorts. Data 
were not normally distributed, so the Mann–Whitney and 
Kruskal–Wallis tests were used for the comparison of the 
groups. The significant threshold was set to p < 0.05. Cor-
relation was tested used the Spearman rank correlation coef-
ficient. Although non-parametric tests were used, linear 
regression lines were added to the figures as guidance. SPSS 
v25.0 (IBM Corp., Armonk, N.Y., USA) was used to fit the 
generalized linear model in the longitudinal cohort. Baseline 
MMSE values (intercept) and rate of change (slope) were 
used as outcomes in linear regression models, with CSF 
N-123 and N-224 tau as predictors. Subjects were divided 
into quartile groups according to CSF N-123 and N-224 
levels at baseline and linear regression models between the 
quartile groups were compared. In the biomarker stability 
study, statistical analysis was carried out using the R pro-
gramming language (version 3.4.3), and all tests were two-
sided with a significance threshold set to p < 0.05. There 
were no corrections made for multiple comparisons, so 
any p values close to 0.05 should be considered explora-
tory. Change in tau N-224 across treatments was tested with 
non-parametric Kruskal–Wallis test. Post hoc analysis of dif-
ferences in biomarker concentration between baseline and 
follow-up and between specific groups was carried out with 
the Mann–Whitney U test. Differences in biomarker con-
centration across varying number of copies of the ε4 allele 
of the APOE gene were also tested in this way. Differences 
in biomarker concentration across treatments depending on 
APOE ε4 genotypes were tested by fitting a linear model 
with an interaction term between treatment and ε4 copies, 
while both age and sex were included as covariates. The 
Spearman rank correlation coefficient was used to assess the 
relationship between change in biomarker concentration and 
age, sex, and change in treatment outcomes as measured by 
the MMSE and ADAS-Cog scales.
Results
Semi‑tryptic tau peptides reveal endogenous 
cleavage sites
Tau was enriched from both brain tissue homogenates 
and CSF using immunoprecipitation (IP) with Tau12 and 
treated with trypsin. In brain tissue, tryptic peptides could 
be detected spanning the whole tau protein, i.e., from the 
N-terminus (acetylated aa 2) to the C-terminus (aa 441). 
Peptides representing all isoforms (0N, 1N, 2N, 3R, and 
4R) were detected. In CSF, only peptides representing the 
N-terminal half of tau were detected; the most C-terminal 
peptide ended at aa 254 and isoform-specific tryptic pep-
tides originating from 0N, 1N, and 2N tau isoforms were 
detected (Fig. 2, Supplementary Table 1). Peptides phos-
phorylated at threonine 181 were detected both in brain 
tissue and in CSF. Furthermore, in both brain and CSF, a 
number of semi-tryptic peptides, i.e. peptides with either 
the N- or C-terminus generated by cleavage by trypsin and 
the other end by endogenous proteases, were identified. 
Among these were peptides ending at aa 123, 124, and 
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125, which led us to investigate non-trypsinated samples 
containing endogenous tau fragments in CSF. We also 
investigated which tau species were immunoprecipitated 
when using antibodies with different binding epitopes 
on tau (Supplementary Table 2). Quantitative data were 
obtained by spiking a stable-isotope-labeled tau 1N4R 
protein into the CSF prior to IP. When performing IP with 
Tau12, tryptic peptides were abundant in the region close 
to the antibody epitope, while intensities decreased when 
moving in the C-terminal direction (Fig. 3). For HT7 and 
BT2, a similar situation was observed; the abundance was 
high close to the epitopes but decreased markedly at the 
C-terminal side, but not as clearly toward the N-termi-
nus (Fig. 3). Together, these data indicate that there is an 
abundance of shorter tau species present in CSF, both at 
the N-terminus and in the mid-region around aa 150–200. 
There are also longer species, but it appears that, shortly 
after aa 221, the abundance drops significantly, and C-ter-
minally of aa 254 no tryptic peptides were detected when 
using these three antibodies (Fig. 3). 
Endogenous tau fragments ending at aa 123 
and 224 are prominent in CSF
Analyses of endogenous tau peptides were performed 
without tryptic digestion, to preserve the naturally occur-
ring peptides in CSF. Using IP-MS with Tau12, 27 differ-
ent endogenous tau fragments were identified by MS/MS 
(excluding oxidized variants at the three available methio-
nine, Met). The majority of these peptides contained the 
N-terminus of tau protein. The N-terminal peptides were 
lacking the Met1 amino acid, and were acetylated at the 
N-terminus. Endogenous species from both the 0N and 
1N isoforms were observed, ranging up to aa 129 and 
including peptides ending C-terminally at aa 123 (Fig. 2 
and Supplementary Table 3). With HT7 and BT2, 37 and 
21 different mid-region species were identified, respec-
tively, ranging from aa 130 to aa 224. With HT7, which 
recovers both T181 and pT181 forms, additional peptides 
phosphorylated at T181 were observed. From the detected 
peptides from the tau mid-region, it was notable that a 
major cleavage site was situated between aa 224 and aa 
Fig. 2  Top: endogenous tau 
species found with N-terminal 
and mid-region-specific 
antibodies (Tau 12 in red, HT7 
in blue, BT2 in orange) and 
neo-epitope-specific antibodies 
(Tau_C123 in lime, Tau_C224 
in green) with selected amino 
acid positions indicated. Align-
ment and numbering refer to 
the 2N isoform; for peptides 
originating from the 0N and 1N 
isoforms, 2N sequence portions 
not included are dimmed. The 
protein schematic structure 
shows the respective antibody 
epitopes and T181. Bottom: 
in black, range (Ac-2-254) of 
tryptic peptides detected in CSF 
with Tau12 (regions with no 
coverage are dimmed). Vertical 
lines indicate possible tryptic 
cleavage sites
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225. The top portion of Fig. 2 shows a summary of the 
endogenous tau species identified.
Newly developed neo‑epitope antibodies are 
specific against aa 123 and aa 224
A total of 17 tau species, all ending C-terminally at aa 
123 and belonging to all three isoforms (0N, 1N, and 2N), 
were identified when performing IP-MS of CSF using 
the anti-tau 123 clone “Tau_1″. Supplementary Fig. 1a 
shows the MS/MS data for the tau peptide Ac-2–63…
103–123 from the 1N isoform (the gap between 63 and 
103 is because aa 64–102 are present only in the 2N iso-
form). Similarly, when performing IP-MS of CSF using 
the anti-tau 224 clone “Tau_F”, ten different tau species 
ending C-terminally at aa 224 were detected. Supplemen-
tary Fig. 1b shows the MS/MS data for the tau peptide 
197–224. The bottom portion of Fig. 2 and Supplemen-
tary Table 3 shows a summary of the endogenous tau 
species detected when using these two antibodies.
Anti‑224 antibody (but not anti‑123) stains 
neurofibrillary tangles
Immunohistochemical analysis with anti-tau 224 antibody 
demonstrated neurofibrillary tangles and dystrophic neurites 
surrounded by neuropil threads, whilst faint punctate neu-
ronal cytoplasmic staining was observed in the normal control 
(Fig. 4a–c). The anti-tau 123 antibody showed weak neuronal 
cytoplasmic staining in AD which was negative in the normal 
control (Fig. 4d–f). Immunohistochemical staining on sequen-
tial sections with anti-AT8 shows the presence of neurofibril-
lary tangles in AD and dystrophic neurites (Fig. 4g) and the 
filamentous structure of the neurofibrillary tangles (Fig. 4h). 
No AT8 staining was present in the normal control (Fig. 4i).
N‑224 tau and t‑tau concentrations show 
a decreasing trend in AD brain samples along Braak 
stages
There was no significant difference in the concentration 
between AD and controls for the N-123 fragment (p = 0.5) 
Fig. 3  Representation of quanti-
tative MS data of tau fragments 
immunoprecipitated with Tau 
12, HT7, and BT2
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(Fig. 5a). The N-224 tau fragment was present in AD brain 
at significantly lower concentrations compared to controls 
(p = 0.01), although not significant when normalized to total 
protein content (p = 0.06) (Fig. 5b). T-tau measurement shows 
significantly lower concentrations in AD compared to controls 
both for absolute and normalized concentrations (p = 0.01 and 
p = 0.004, respectively) (Fig. 5c). When dividing the samples 
by Braak staging, the N-224 fragment and t-tau tended to 
decrease from stage I to VI when including all samples and in 
AD samples from stage III–VI (Fig. 5e). No visible trend is 
present for the fragment N-123 (Fig. 5d) or for any of the tau 
fragments in controls.
N‑123 and N‑224 tau concentrations in CSF are 
significantly increased in AD in a discovery cohort
The CSF concentration of tau N-123 was significantly higher 
in AD compared to non-AD subjects (p < 0.001) (Supple-
mentary Fig. 2a). There was a significant positive correla-
tion between the N-123 fragment and t-tau in the AD group 
(r = 0.56, p = 0.01) but not in the control group (r = 0.15, 
p = 0.58). Similarly, the concentration of the tau N-224 was 
significantly higher in AD compared to controls (p < 0.001) 
(Supplementary Fig. 2b). Furthermore, a significant positive 
correlation was found between tau N-224 tau and t-tau in the 
Fig. 4  Tau immunohistochem-
istry in Alzheimer’s disease 
(a and b; d and e; g and h) 
and a neurologically normal 
control (c, f, and i). Anti-tau 
224 immunohistochemistry 
shows neurofibrillary tangles 
(a, arrow) and dystrophic 
neurites (a, double arrow) sur-
rounded by neuropil threads. 
Neurofibrillary tangles show at 
higher magnification (b). Faint 
punctuate neuronal cytoplas-
mic staining was observed in 
the normal control. Neurons 
in AD are weakly positive for 
anti-tau 123 and negative in the 
normal control. For comparison, 
sequential sections were immu-
nohistochemically stained with 
AT8 to show the presence of 
neurofibrillary tangles in AD (g, 
arrow), dystrophic neurites (g, 
double arrow), and filamentous 
structure of the neurofibrillary 
tangles (h). AT8 staining is 
absent in the normal control. 
Bar (in i) represents 50 µm in 
a, c, d, f, g, and i; 20 µm in b, 
e, and h 
Alzheimer’s disease Control
Ta
u2
24
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u1
23
A
T8
a b c
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control group (r = 0.65, p = 0.004, α < 0.05) but not in the 
AD group (r = 0.432, p = 0.1308). N-123 and N-224 showed 
a positive correlation in AD (r = 0.9, p < 0.0001) but not in 
controls. A significant correlation was also found between 
N-224 tau and N-mid domain tau (N-mid, aa 9–198) in AD 
(r = 0.72, p = 0.01) as well as in controls (r = 0.69, p = 0.01).
N‑224 and x‑224 tau (but not N‑123) concentrations 
in CSF are significantly increased in AD 
in a validation cohort
For tau N-123, we observed an opposite behaviour compared 
to the discovery cohort, with significantly higher concentra-
tions in controls vs. AD (p = 0.001) (Fig. 6a). N-123 con-
centrations did not correlate with t-tau (Fig. 6d). In contrast, 
tau N-224 was significantly higher in patients with AD com-
pared to controls (p < 0.001) (Fig. 6b). Tau N-224 correlated 
to t-tau in both AD and controls (r = 0.62 vs. r = 0.75) and 
the correlation was significant in both groups (p < 0.0001) 
(Fig. 6e). N-123 and N-224 had a positive correlation in con-
trols (r = 0.5, p < 0.0001) but not in AD. N-224 also shows 
a significant correlation to N-mid domain tau (N-mid, aa 
9–198), (r = 0.81 and r = 0.76 for AD and controls, respec-
tively, p < 0.0001 for both). Tau x-224 concentration was 
significantly higher in AD CSF samples compared to con-
trols (p < 0.0001) (Fig. 6c). Tau x-224 correlates positively 
to t-tau in AD and control cohorts (r = 0.8 and 0.9, respec-
tively) and both correlations are significant (p < 0.0001) 
(Fig. 6f).
N‑123 and N‑224 tau baseline concentrations in CSF 
are related to severity of cognitive impairment 
in a longitudinal cohort
Baseline levels of the N-123 and N-224 fragments were sig-
nificantly higher in AD vs. OND (p = 0.03 and 0.002, respec-
tively), mild cognitive impairment due to AD (MCI-AD) vs. 
MCI (p = 0.01; p = 0.002), and MCI-AD vs. OND (p = 0.001; 
p < 0.0001) (Fig. 7a, b). Group differences for N-123 and 
N-224 did not change significantly when controlling for age 
and gender effects (p > 0.05). N-123 and N-224 showed a 
positive correlation in MCI (r = 0.59, p = 0.001), MCI-AD 
(r = 0.61, p = 0.004), and OND group (r = 0.67, p = 0.005), 
but not in AD. Based on the baseline CSF N-123 and N-224 
tau levels, AD, MCI-AD and MCI groups were classified 
into quartiles (Q1, Q2, Q3, and Q4), which were tested for 
association with disease progression as examined by longi-
tudinal change in Mini-Mental State Examination (MMSE). 
Fig. 5  Brain levels (normal-
ized for total protein content) of 
N-123 (a), N-224 (b) fragments, 
and t-tau (c) in Alzheimer’s 
disease and controls and in 
AD over Braak stages III–VI 
(d, e, f) (lines representing 
the median, bars representing 
interquartile range)
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MMSE score decreased significantly over years from base-
line for the highest quartile (Q4) for both fragments (N-123: 
adj. R2 = 0.36, β = − 0.61, p = 0.0001; N-224: adj. R2 = 0.34, 
β = − 0.58, p = 0.0002) (Fig. 7c, d). A significant decrease 
at MMSE score in Q4 was not observed for t-tau and p-tau 
(p > 0.05).
N‑224 tau does not correlate to t‑tau and p‑tau 
in PSP and CBS
CSF levels of N-224 tau were significantly lower in PSP 
and CBS vs. both AD (p < 0.0001, both) and controls (PSP: 
p < 0.0001; CBS: p < 0.002) (Fig. 8a). CSF N-224 tau con-
centrations did not significantly correlate to t-tau in both 
PSP (r = 0.09) and CBS (r = 0.33) (Fig. 8b). Correlation 
to p-tau was significant in PSP (r = 0.54, p = 0.002) but 
not in CBS (r = 0.33) (Fig. 8c). After removing the Aβ+ 
subjects, no significant correlation with t-tau or p-tau was 
present in any of the groups (PSP: r = 0.48 for both: CBS: 
r = 0.39, r = 0.11) (Fig. 8e–f). Concentrations of N-224 tau 
in Aβ− PSP were significantly lower than in AD and con-
trols (p < 0.0001), while, in CBS, concentrations were sig-
nificantly lower only when compared to AD (p = 0.0001) 
(Fig. 8d). N-123 tau concentrations were below LLOQ in 
8 out of 15 (53.3%) CBS cases and 19 out of 31 (61.3%) 
PSP cases.
N‑224 tau concentrations in CSF are not affected 
by treatment with AChE inhibitors
Levels of tau N-224 did not significantly differ between 
baseline and follow-up (p = 0.78), with an average CV of 
13.4% and 12% change (Supplementary Fig. 3a, b, c). The 
concentrations were not significantly different across drug 
treatments (p = 0.08). There were no significant differences 
between specific groups when comparing donepezil to riv-
astigmine treatment (p = 0.28) and donepezil  to  galan-
tamine (p = 0.37). Moreover, N-224 tau levels did not differ 
Fig. 6  Validation cohort. Left 
column: concentration range of 
N-123 (a), N-224 (b), and x-224 
(c) fragments in AD and con-
trols (lines representing median; 
bars representing interquartile 
range; in a, bars removed due to 
the LOG scale). Right column: 
correlation of N-123 (d), N-224 
(e), and x-224 (f) fragment to 
t-tau and linear regression in 
AD and controls 10
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Fig. 7  Longitudinal cohort. a, b 
Concentration range of N-123 
(a) and N-224 (b) fragments 
in AD, MCI, and MCI-AD and 
OND (lines representing the 
median, bars representing inter-
quartile range). c, d Disease 
progression over time in AD, 
MCI-AD and MCI cohorts, as 
measured by change in MMSE 
scores. Higher levels of CSF 
N-123 (a) and N-224 (b) tau 
at baseline are related to faster 
decline. N-123: Quartile (Q) 1: 
n = 16, Q2: n = 15, Q3: n = 15 
and Q4: n = 16; N-224: Q1: 
n = 17, Q2: n = 17, Q3: n = 17, 
and Q4: n = 17
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Fig. 8  PSP and CBS cohort. a, d Concentration of N-224 tau in PSP 
and CBS (a: Aβ+ and Aβ; d: Aβ− only) compared to AD and con-
trols from the validation cohort (lines representing the median, bars 
representing interquartile range). b, c, e, f Correlation to t-tau (b) and 
p-tau (c) and linear regression in PSP and CBS cohorts (b, c: Aβ+ 
and Aβ; e, f: Aβ− only)
 Acta Neuropathologica
1 3
significantly depending on number of APOE ε4 copies 
(p = 0.48). There was no interaction effect between treat-
ment and APOE ε4 copies for tau N-224 (p = 0.35). There 
was no strong association between change in tau N-224 and 
either change in MMSE (r = − 0.12, p = 0.38) or change in 
ADAS-Cog (r = 0.03, p = 0.81). Tau N-224 did not differ 
across sex (p = 0.22), or age (p = 0.08).
N‑224 tau specifically present in NDEV and N‑123 
tau in both NDEV and PDEV
The N-123 tau fragment was measurable in all EV lysates 
with no significant difference between NDEVs, i.e., 
L1CAM-positive samples, and peripherally derived EVs 
(PDEVs), i.e., supernatants left after L1CAM-positive 
EVs had been bound to the beads. There were no differ-
ences comparing levels of tau N-123 in NDEVs or PDEVs 
comparing AD and control samples. Comparable concentra-
tions of the fragments were observed within and between 
cohorts (Fig. 9a). Conversely, the N-224 tau fragment was 
significantly higher in NDEV lysates compared to PDEV 
lysates (p = 0.03) in both AD and control groups. Fold dif-
ferences between average concentrations of N-224 tau in 
NDEV samples compared to PDEV were 148 and 70 in the 
AD and control group, respectively. Differences between AD 
and control NDEV samples were not significant (Fig. 9b).
Discussion
Using IP-MS analysis with anti-tau antibodies (Tau 12, HT7, 
and BT2), we collected quantitative data demonstrating sev-
eral tau fragments in CSF, both at the N-terminus and in 
the mid-region (Fig. 2). Shortly after aa 221, the abundance 
of the fragment intensities dropped significantly and C-ter-
minally of aa 254 no tryptic peptides were detected when 
using these three antibodies (Fig. 3). The two major tau 
pools detected were composed of peptides ending at aa 123 
and aa 224, respectively, suggesting prominent proteolytic 
cleavage of the protein around these sites. It should be noted 
that the absence of even longer peptides corresponding to the 
data from trypsinated CSF samples is likely a methodologi-
cal bias; MS favors detection and identification of smaller 
peptides and there are likely longer tau variants present in 
CSF which evade identification with the LC–MS configura-
tion used in the current study. Furthermore, the choice of a 
C18 column for separation may also have contributed to the 
bias against longer peptides.
In support of the findings in the present study, the previ-
ous studies in brain tissue identified N-terminally truncated 
fragments starting from aa 124 and proteomics studies on 
CSF confirmed the presence of fragments ending at aa 224 
[9, 18, 35]. We, therefore, generated antibodies against these 
specific fragment epitopes and confirmed their specificity 
through ELISA cross-reactivity tests as well as IP-MS. The 
antibodies were successfully tested for immunohistochem-
istry on AD and control brain slices, and used to develop 
targeted immunoassays. Validation of immunoassays on dif-
ferent platforms (ELISA, Simoa), and their application on 
exosome lysates, soluble fraction of brain extracts and CSF 
from four independent cohorts of AD and control subjects, 
showed that the novel assays were specific, sensitive, and 
robust, with fragment concentrations within the calibration 
range.
Immunohistochemical staining showed positivity to the 
anti-tau 224 antibody in neurofibrillary tangles and neuropil 
threads (Fig. 4a, b), suggesting that this fragment is depos-
ited in AD and colocalized with the tangles. Data from brain 
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extracts showed an apparent decreasing trend for the N-224 
tau fragment over the course of disease (Braak III–VI), 
with lower concentration in AD brain compared to con-
trol, although the difference was not statistically significant 
when normalized to total protein content (Fig. 5b, e). T-tau 
shows the same behaviour in brain extracts, being signifi-
cantly lower in AD brain compared to controls, even when 
normalized to total protein content (Fig. 5c, f). Although it 
might appear counterintuitive, this behaviour is justified by 
the technique used for extraction: RIPA buffer extracts all of 
the fractions soluble in weak detergents and also a propor-
tion of tau insoluble in no-detergent or non-ionic detergent 
conditions, but not tau aggregated into tangles, as it would 
require additional extraction steps. These findings suggest 
that N-224 might be trapped in the fuzzy coat of tau tangles 
and, therefore, less likely to be extracted with this technique 
in samples from later stages of disease, although these obser-
vation need to be confirmed with further experiments, i.e., 
sarkosyl extraction and treatment of the sarkosyl-insoluble 
pellet. On the other hand, in CSF the N-224 tau fragment 
shows an opposite behaviour to the brain, being significantly 
higher in AD CSF compared to control and in MCI-AD com-
pared to stable MCI (Figs. 6b, 7b). Thus, brain and CSF give 
us complementary information about tau metabolism in AD 
compared to controls.
It seems, therefore, that, in the CNS, there is a disease-
related upregulated cleavage at this site which leads to 
enhanced release from neurons of the N-terminal fragment, 
ultimately leading to higher CSF concentration of the frag-
ment and a deposition into tangles. At a tangle level, the 
224-cleaved tau might, therefore, be an indirect marker of 
ongoing tangle formation. Another potential explanation for 
the results (with similar practical implications regarding the 
possible association of the fragment with tangle pathology) 
is that the production of the fragment could be enhanced in 
the fuzzy coat of tangles. These promising results open up 
for the investigation of tau fragments in tangle pathology, 
using various techniques, such as laser capture of tangles and 
more refined extraction techniques.
Several studies have been published on N-terminal cleav-
age of tau from proteases of the calpain and caspase fam-
ily [20, 25]. The N-224 might also represent the neurotoxic 
N-terminal tau fragment of 20-22 kDa that has been shown 
by western blot in several studies [1–4, 8]. Other studies 
have also shown the presence of N-terminal fragments rang-
ing from 20 to 40 kDa in CSF [30]. Secretion of N-terminal 
tau fragments has also been previously described [36]. Fur-
ther studies to establish which enzyme is responsible for this 
cleavage and whether this activity is specifically upregulated 
in AD are needed.
The fragment x-224 proved to be less interesting than 
N-224, meaning that it more tightly correlated with t-tau in 
AD and controls, probably due to the overlapping region of 
interest of the assays used to measure the two tau entities 
(aa 159–240). Tau N-224, on the other hand, might repre-
sent the product of a different metabolic route affecting the 
N-terminus of the protein as opposed to the mid-region pool.
When analyzing baseline CSF values of N-224 tau 
in subjects monitored over time by means of MMSE, we 
observed that the magnitude of cognitive decline is related to 
the initial concentration of the fragment (Fig. 7d). It seems, 
therefore, that not only the N-224 fragment is AD-related, 
but its concentration could also have a predictive value of 
worse cognitive outcome. In the previous studies, no cor-
relation was found between baseline core CSF biomarker 
levels and follow-up cognitive scores [39]. One limitation 
of our study is that the subjects were monitored by MMSE, 
which is not the optimal test to detect the early AD-related 
changes in cognition [40]. Future studies on prognostic value 
of tau fragments should be performed in longitudinal cohorts 
where cognitive assessment at follow-up includes ADAS-
Cog and delayed word recall [34].
When comparing AD to primary tauopathies PSP and 
CBS, we observe that CSF N-224 tau concentrations are sig-
nificantly decreased in PSP and CBS, being even lower than 
in controls. We have also measured core AD CSF biomarkers 
to discriminate AD-like PSP and CBS. Even after excluding 
CSF Aβ+ subjects, the same behaviour is observed, with 
the loss of significant difference between CBS and controls 
possibly due to a statistical power issue (seven CBS cases 
vs. 50 controls). A similar behaviour in PSP and CBS has 
been observed before for t-tau and p-tau [21, 41, 42]. This 
might be due to an overall lower concentration of CSF tau 
in the primary tauopathies, and it is not known whether this 
is due to reduced tau production, reduced secretion into the 
CSF, or both. Difference in the distribution of tau pathology 
between neurons (AD) and glia (PSP and CBD) might also 
account for this behaviour. The lack of correlation of N-224 
tau to p-tau and t-tau suggests a different underlying disease 
mechanism compared to AD, which does not include cleav-
age of N-terminal tau. Parallel investigation of N-224 tau, 
t-tau, and p-tau in PSP and CBS could help to understand 
these different mechanisms and add to the information from 
classic CSF tau biomarkers.
In terms of stability and predictive power, it is reassuring 
that the levels of N-224 tau in AD subjects were basically 
unaffected by AChE inhibitor treatment at 6-month follow-
up, regardless of APOE status, age, gender, or drug type. 
This type of study would benefit from a longer follow-up, to 
evaluate possible long-term oscillations in the concentration 
and association with cognitive scores.
Immunohistochemical data on N-123 tau showed only 
a faint positivity of neuronal staining with anti-tau 123 
and mostly in the cytoplasm, which makes the presence of 
N-123 tau in the tangles unlikely and reinforces the idea of 
an active secretion of the fragment (Fig. 4d–f). A similar 
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behaviour for the N-123 fragment was observed in CSF 
and brain extracts, with a wide range of concentrations in 
both AD and control cohorts (Figs. 5a, 6a). More precisely, 
the difference in concentration between the two groups is 
not consistent throughout the cohorts, and no trend is vis-
ible over the course of disease as measured by Braak stag-
ing. Although the N-123 fragment does not seem to have 
a clear diagnostic role, the previous publications suggest 
that the function of tau is affected by N-terminal shedding 
and that N-terminal integrity is necessary for microtubule 
stability, tau solubility, and cell survival [5, 18, 24]. One 
possible speculation is that this tau fragment might repre-
sent a general marker for tau metabolism occurring in CNS 
and peripheral nervous system, a hypothesis reinforced by 
its presence in the PDEV. However, no indications have 
been found on how this relates to the disease state and/or 
stage, although higher CSF levels at baseline are related 
to higher rate of cognitive decline at follow-up as meas-
ured by decline at MMSE (Fig. 7c). Data from serum EVs 
do not corroborate the brain or disease specificity of the 
fragment, showing similar level of N-123 in NDEV and 
PDEV from AD and controls (Fig. 9a). These findings 
are opposed to the ones on N-224 tau in serum EV lysate; 
here, N-224 appears to be brain-specific, showing concen-
trations close to zero in PDEV, although not being decisive 
in discriminating between AD and controls (Fig. 9b). It 
is possible that there is an intrinsic balance between tau 
fragmentation and stability, and that the N-123 fragment 
could be a marker of physiological processes within a 
given range of concentrations. It is also evident that N-123 
is more abundant tau fragment than N-224, being readily 
measureable by ELISA, which is much less sensitive than 
Simoa. Moreover, no correlation between the concentra-
tions of N-123 and N-224 tau is present in the AD groups 
of the validation and longitudinal cohorts, while it is pre-
sent in control, OND, MCI, and MCI-AD groups. The bio-
logical mechanism underlying the difference in abundance 
between N-123 and N-224 is currently unknown, but the 
aggregated results suggest that the two fragments might 
reflect different mechanism of tau processing in AD.
In conclusion, our data suggest that, among the several 
fragments of tau present in CSF, there are two major pools 
consisting of tau species cleaved at either aa 123 or 224. 
While cleavage generating tau N-123 could be part of the 
normal function of tau turnover, the generation of tau N-224 
is related to AD. In support of this hypothesis is the lack 
of consistent differences of CSF N-123 tau levels compar-
ing AD and control, while fragments ending at aa 224 are 
significantly higher in AD CSF compared to control and 
relate to the decrease in cognitive performance over time. 
Future studies evaluating whether these tau cleavages may 
promote tau aggregation and propagation are of high inter-
est. Furthermore, studies in primary tauopathies show great 
promise for elucidating the role of differential tau processing 
in AD compared to the other tauopathies.
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